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Here we present evidence for previously unappreciated B-cell immune dysregulation during acute Epstein-Barr virus (EBV)-
associated infectious mononucleosis (IM). Longitudinal analyses revealed that patients with acute IM have undetectable EBV-
specific neutralizing antibodies and gp350-specific B-cell responses, which were associated with a significant reduction in mem-
ory B cells and no evidence of circulating antibody-secreting cells. These observations correlate with dysregulation of tumor
necrosis factor family members BAFF and APRIL and increased expression of FAS on circulating B cells.
Epstein-Barr virus (EBV) is a human herpesvirus that infectsmore than 90% of the world’s population (1). While benign
and asymptomatic for the most part, EBV infection has the poten-
tial to cause many nonmalignant and malignant diseases of lym-
phoid and epithelial origins (2). EBV infection during childhood
is mostly asymptomatic; however, primary exposure during ado-
lescence manifests itself as infectious mononucleosis (IM) in 30 to
70% of cases (3–7). It is not known why some individuals are more
likely than others to develop clinical symptoms from delayed in-
fection (8). While CD8T cells play a central protective role in the
control of latent EBV infection, they are also likely to be the main
mediators of disease during IM (9, 10). These observations suggest
that other immune response mediators are likely important for
the prevention of acute symptomatic EBV infection. Observations
from a recent phase II clinical trial suggested that the induction of
neutralizing antibodies can prevent symptomatic acute IM fol-
lowing primary infection (11). Despite these encouraging results,
very little emphasis has been placed upon the investigation of hu-
moral immunity during primary infection, although it was shown
over 40 years ago that efficient EBV neutralization does not de-
velop until well after convalescence (12), suggesting that defects in
humoral immunity could contribute to the disease burden during
acute IM. The goal of this study was therefore to investigate the
role of humoral immunity during primary symptomatic EBV in-
fection. We hypothesized that this increased viral replication dur-
ing acute IM may be linked to impaired B-cell responses.
To test this hypothesis, we assessed EBV-specific neutralizing
antibody responses at the time of diagnosis of acute IM and at least
6 months following recovery from clinical symptoms of acute viral
infection. Neutralizing antibody levels were assessed with an EBV
transformation assay as previously described (13, 14). As shown in
Fig. 1A, none of the patients with acute IM had detectable anti-
EBV neutralizing antibody responses during the acute stage of
infection and the levels of neutralizing antibodies significantly in-
creased as these patients recovered from acute viral infection. The
levels of EBV-neutralizing antibodies in many patients remained
well below the levels seen in asymptomatic virus carriers, even
after recovery from acute IM (Fig. 1A).
Earlier studies have shown that EBV-encoded glycoprotein
gp350 is one of the major immunodominant antigens in antiviral
neutralizing antibody responses (15, 16). To determine whether
lack of viral neutralization was associated with impaired induction
of a gp350-specific response, gp350 antibody titers were assessed
in the serum of IM patients. As shown in Fig. 1B and C, the levels
of anti-gp350 Ig and total anti-gp350 IgG in patients with acute
IM were significantly lower than the levels of gp350-specific Ig and
IgG in patients who had recovered from clinical symptoms of
acute viral infection and in asymptomatic virus carriers. To fur-
ther confirm the impaired antiviral humoral responses during
acute IM, we next quantitated the circulating EBV-specific mem-
ory B cells (MBCs) with enzyme-linked immunospot (ELISPOT)
assays. Consistent with the data presented in Fig. 1A, most patients
with acute infection had significantly lower numbers of gp350-
specific MBCs than did age-matched healthy virus carriers (Fig.
1D). A significant increase in gp350-specific MBCs was observed
following the resolution of acute IM symptoms.
To delineate the potential reason for the lack of EBV-specific
neutralizing antibodies, we performed a longitudinal analysis of
the frequency of MBCs (CD3 CD19 CD20 CD27hi) and plas-
mablasts (CD3CD19CD20lo CD27hi CD38hi) in the peripheral
blood of IM patients. Representative gating analyses of these B-cell
subsets are shown in Fig. 2A. These analyses revealed a significant
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reduction in the frequency of MBCs during acute infection (Fig.
2B). The frequency of MBCs remained low even after recovery
compared with that in healthy virus carriers (Fig. 2B). Interest-
ingly, despite ongoing viral replication, there was no significant
increase in the frequency of plasmablasts in acute IM patients
compared with that in asymptomatic healthy virus carriers (Fig.
2C). This finding is in contrast to previous studies of other viral
infections, including those caused by influenza, dengue and respi-
ratory syncytial viruses, which showed that increased frequencies
of plasmablasts in the peripheral blood are readily detectable dur-
ing the acute phase of infection (17–19).
We next explored the possibility that the low frequency of plas-
mablasts in acute IM is due to the inability of B cells to mature into
plasmablasts. Peripheral blood mononuclear cells (PBMCs) from
acute IM patients and latent EBV carriers were stimulated with
polyclonal B-cell stimulators and assessed for the frequencies of
plasmablasts and total IgG-producing B cells. Consistent with the
data presented above, conversion of B cells to plasmablasts was
significantly lower in acute IM patients than in latent EBV carriers
(Fig. 3A and B). The efficacy of B-cell conversion also appeared to
inversely correlate with the severity of clinical symptoms during
acute EBV infection. Although the difference was not statistically
significant, patients diagnosed with severe clinical symptoms typ-
ically showed fewer IgG-producing cells (Fig. 3C). In vitro infec-
tion of healthy PBMCs with EBV did not prevent the conversion
of B cells into IgG-producing cells (data not shown), so direct
infection of B cells by EBV is unlikely to lead to a defect in the
maturation of MBCs into plasmablasts.
Finally, the impairment of B-cell-mediated immune regula-
tion during acute IM was further evident by dysregulated ex-
pression of tumor necrosis factor (TNF) superfamily ligands
and receptors BAFF (B-cell-activating factor) and APRIL (B-
cell proliferation-inducing ligand), which play a critical role in
B-cell survival, maturation, and activation (20, 21). These li-
gands mediate their activity through interaction with BAFF-R
(BAFF receptor) and BCMA (B-cell maturation antigen) (22).
Earlier studies have shown that a defect in signaling through
these receptors can cause impairment of T-cell-dependent hu-
moral immunity and in the generation of MBCs (21). Acute IM
patients showed increased levels of BAFF in plasma and down-
regulated expression of BAFF-R on circulating B cells (Fig. 4A
and B). In contrast, the levels of APRIL in plasma were signif-
icantly lower, whereas BCMA expression on circulating B cells
was significantly increased (Fig. 4C and D). Furthermore, we
also observed significantly higher levels of FAS on B cells and
FAS ligand (FAS-L) in plasma during acute IM, which de-
creased as the disease resolved and eventually reached the levels
seen in healthy virus carriers (Fig. 4F). This increased expres-
sion of FAS on B cells may indicate increased susceptibility to
FAS-mediated death.
In this study, we have shown that during primary symptomatic
EBV infection, there is delayed induction of EBV-specific neutral-
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FIG 1 Delayed induction of gp350-specific neutralizing antibody response following acute EBV infection. (A) Serial dilutions of heat-inactivated plasma were
incubated with EBV B95-8 and then with PBMC from an EBV-seronegative donor for 6 weeks. Data represent the effective dilution of plasma that inhibits B-cell
transformation by 50%. (B) EBV gp350-specific Ig titers were evaluated by enzyme-linked immunosorbent assay. Data represent the inverse titer that induces
50% of the maximal optical density at 450 nm. (C) EBV gp350-specific IgG titers were evaluated by enzyme-linked immunosorbent assay. Data represent the
inverse titer that induces 50% of the maximal optical density at 450 nm. (D) Frequency of IgG-secreting gp350-specific B cells determined by ELISPOT assay.
PBMCs from IM patients and latent virus carriers were cultured in vitro for 6 days to stimulate antibody production from MBCs. Data represent the proportion
of antigen-specific cells relative to the total IgG-producing B-cell population. Statistical analysis was performed with a Wilcoxon matched-pair signed-rank test
to compare measurements at two time points for the same individual, and comparison of unpaired groups was performed by Mann-Whitney test. **, P 0.01;
***, P 0.001; ****, P 0.0001.
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izing antibodies and gp350-specific MBCs and that this is coinci-
dent with homeostatic dysregulation in the global B-cell compart-
ment. Interestingly, while other EBV-specific antibody responses,
including those targeting EBV nuclear antigen 1, are not induced
until well after convalescence, B-cell responses to the viral capsid
antigens (VCA) and early antigens (EA) are readily detected dur-
ing acute EBV infection. While the precise mechanism of the dif-
ferential kinetics of B-cell responses to VCA/EA and gp350 re-
FIG 2 Impact of acute EBV infection on the peripheral B-cell compartment. PBMCs from IM patients and latent virus carriers were incubated with fluorescently
labeled antibodies specific for CD19, CD20, CD27, and CD38, and then the frequencies of MBCs and plasmablasts were assessed by flow cytometry. (A)
Representative analysis of the gating strategy for MBCs and plasmablasts from a single donor is shown. SSC, side scatter; FSC, side scatter; ASC, antibody-
secreting cells. (B, C) Box-and-whisker plots represent the mean and range of either MBCs (B) or plasmablasts (C) in PBMCs. Dots represent data from individual
donors. Statistical analysis was performed by one-way analysis of variance. *, P 0.05; ****, P 0.0001.
FIG 3 Acute EBV infection is associated with a global defect in conversion into antibody-secreting cells (ASC). PBMCs from IM patients and latent virus carriers
were cultured in vitro for 6 days with a B-cell stimulation cocktail (pokeweed mitogen extract, Staphylococcus aureus protein A, CpG ODN 2006, and interleukin-
10) to stimulate conversion into plasmablasts. Cultured cells were then assessed for the frequency of plasmablasts by flow cytometry or for the capacity to produce
IgG by ELISPOT assay. Box-and-whisker plots represent the mean and range of either plasmablasts (A) or IgG-producing cells (B, C). Dots represent data from
individual donors. Statistical analysis was performed by one-way analysis of variance. ***, P 0.001; ****, P 0.0001.
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mains to be determined, we hypothesize that while early priming
of B-cell responses to VCA/EA can be induced rapidly after infec-
tion because of the abundance of these proteins or their ease of
processing by the immune system, B-cell responses to other less
abundant or less efficiently processed antigens are not induced as
easily. Subsequently, the onset of B-cell immune dysregulation
restricts the induction of an efficient neutralizing antibody re-
sponse, which likely contributes to the increased viral load, lead-
ing to uncontrolled activation of EBV-specific CD8 T cells. Fur-
ther studies on the mechanism of this impaired B-cell immunity
may explain how the immune dysregulation observed during
acute IM leads to the poor induction of EBV-specific neutralizing
antibody responses and help us to design better therapeutic
and/or prophylactic strategies to prevent acute IM symptoms and
perhaps reduce the risk of developing more serious EBV-associ-
ated diseases (23).
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